GLOBAL MARKETS-Stocks nurse record monthly gains ahead of ECB

Published 30/04/2020, 12:30
Updated 30/04/2020, 12:36
© Reuters.

* Gilead's remdesivir shows promise in clinical trial
* MSCI world stocks heads for best month on record
* Major currencies in holding pattern
* Oil markets still wild, Brent last up 11.8%
* ECB to hold press conference at 1330 GMT

By Marc Jones
LONDON, April 30 (Reuters) - World stocks headed for their
best month on record on Thursday, as encouraging early results
from a COVID-19 treatment trial and expectations of more
European Central Bank (ECB) stimulus later in the day helped
ease the pain of February and March.
Europe saw a cautious morning with oil firm Shell's first
dividend cut in 80 years a record drop in euro
zone first quarter GDP and a surge in German
unemployment all giving traders an excuse for some pre-ECB
profit taking. .EU
Not that it mattered. Easing coronavirus worries mean the
STOXX 600 .STOXX is up more than 25% over the last six weeks.
April will be Europe's best month since 2009 while for MSCI's
World Index, it is looking like the best since it started in the
late 1980s. .EU "We have gone back to a turbo-charged version of the great
financial crisis," said Simon Fennell, a portfolio manager in
William Blair's global equity team, referring to how markets
have surged on mass central bank and government stimulus.
"Today we will also see if the ECB is going to go to 1
trillion or beyond with its PEPP programme," he added, a
reference to the central bank's beefed-up emergency bond buying
scheme. A 1.4% rise in MSCI's broadest index of Asia-Pacific shares,
excluding Japan, .MIAPJ0000PUS kept it tracking towards a
weekly gain of more than 5%, its best in three weeks.
Optimism was also driven by Wall Street's strong finish on
Wednesday after partial results from a trial of Gilead's
GILD.O antiviral drug remdesivir, suggested it could help
speed recovery from COVID-19, the respiratory disease caused by
the new coronavirus. Japan's Nikkei .N225 jumped 2.15% to a seven-week high and
Australia's ASX 200 .AXJO rose 2.4%, with the mood further
supported by South Korea reporting no new domestic coronavirus
cases for the first time since its Feb. 29 peak.
More caution was evident in other asset classes, with the
U.S. dollar steady against most of the other major currencies
/FRX and German Bund yields - which move inversely to prices -
dipping to a one-month low ahead of the expected ECB moves.
"It's a hope-based rally rather than an evidence-based
rally," said Anthony Doyle, cross-asset specialist at fund
manager Fidelity International in Sydney.
There were still worries about a second wave of infections,
he said, adding that huge piles of cash waiting to go back into
the markets suggest investor confidence remained nervy.

HEY BIG SPENDERS
It's not only equity markets that have rebounded sharply
this month. Gold is set for its best month in four years
GOL/ and copper, which is seen as a something of bellwether of
global industry, was on track for its best performance since
December 2017. MET/L
Markets have been excited by the prospect of a COVID-19
treatment because it may help economies emerge from lockdowns.
Partial results from the 1,063-patient U.S. government trial
of Gilead's remdesivir were hailed as "highly significant" by
the top U.S. infectious disease official, Anthony Fauci.
They showed hospitalised COVID-19 patients given the drug
recovered in 11 days, compared with 15 days for patients given a
placebo, and a slightly lower death rate.
But since treatment hopes don't seem to take into account
regulatory and distribution difficulties, should a treatment be
found, currency and bond markets were more circumspect.
"Any positive medical development is helpful," said Westpac
FX analyst Sean Callow. "But no-one should be counting on a
major breakthrough - the key for markets is control of the
spread of the virus."
The yield on benchmark U.S. 10-year Treasuries US10YT=RR
dipped to 0.6075 % meanwhile, after the U.S. Federal Reserve
left interest rates near zero and gave no indication of lifting
them any time soon. BlackRock's Chief Investment Officer of Global Fixed Income,
Rick Rieder, who oversees $2.2 trillion of assets, said it
showed the Fed was committed to doing "whatever it takes".
Blackrock expects the U.S. central bank to purchase the
equivalent of at least $1.5 trillion in Treasuries over the
remainder of the year. Along with other crisis-fighting measures
its balance sheet will balloon by $7 trillion, or $26 billion
per day.
"The magnitude of the policy response to this economic
crisis is simply stunning," Rieder added.
With all that to digest, the dollar held its ground against
the resurgent Australian dollar AUD=D3 for the first time in a
week and barely budged against the euro EUR= which was at
$1.0875 as the ECB's 1145 GMT statement and 1230 GMT news
conference loomed. FRX/
Gold XAU= was a touch higher at $1,715 per ounce and
things were still wild in oil markets. Brent crude LCOc1 and
U.S. crude CLc1 futures rose $2.1 and $2.4 - or 11.8% and
16.2% a barrel - respectively amid optimism that a storage
squeeze is not as bad as first feared, and that demand for fuel
may soon return. O/R

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Global assets http://tmsnrt.rs/2jvdmXl
Global currencies vs. dollar http://tmsnrt.rs/2egbfVh
Emerging markets http://tmsnrt.rs/2ihRugV
MSCI All Country Wolrd Index Market Cap http://tmsnrt.rs/2EmTD6j
April bounce back for world markets IMAGE https://tmsnrt.rs/3aQR3S6
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
(Additional Reporting by Tom Westbrook in Singapore and Swati
Pandey in Sydney; Editing by Alex Richardson, Kirsten Donovan)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.